Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Jul;28(7):e70006.
doi: 10.1002/jia2.70006.

"A cure might help, but it won't erase it all": a qualitative study of policy challenges and priorities for long-term survivors of HIV in the United States

Affiliations

"A cure might help, but it won't erase it all": a qualitative study of policy challenges and priorities for long-term survivors of HIV in the United States

Ali Ahmed et al. J Int AIDS Soc. 2025 Jul.

Abstract

Introduction: Long-term survivors (LTS) of HIV, including individuals diagnosed before the availability of effective antiretroviral therapy (ART), have played a pivotal role in shaping the HIV response. Despite an increase in their number in the United States, their unique medical, social and economic challenges remain underrepresented in HIV policy and research, particularly in the context of HIV cure advancements. While an HIV cure may alleviate ART-related burdens, LTS fear unintended consequences, including the potential loss of critical social benefits, economic support and healthcare access. This study explores the policy priorities of LTS, addressing their current unmet needs and the broader implications of an HIV cure.

Methods: We conducted qualitative interviews with 32 LTS across diverse racial, gender and geographic backgrounds, recruited through community-based organizations and research networks from 2023 to 2024. Using inductive thematic analysis, we identified key policy concerns and recommendations based on participants' lived experiences. Data collection continued until thematic saturation was reached.

Results: LTS emphasized four pressing policy domains: (1) Persistent Healthcare Disparities: Participants reported fragmented Medicare and Medicaid coverage, limited access to essential services (e.g. dental, vision and mental healthcare), and ongoing stigma and discrimination in healthcare settings. (2) Social and Economic Precarity: Housing instability, financial insecurity and employment barriers disproportionately affect LTS, many of whom face systemic barriers to re-entering the workforce. (3) Policy Implications of an HIV Cure: Participants voiced concerns that an HIV cure, while promising, could result in disqualification from disability and social assistance programmes, exacerbating socio-economic vulnerabilities. (4) Structural Reforms for LTS Inclusion: LTS underscored the urgent need for their direct involvement in HIV research, policy development and decision-making to ensure equitable, community-driven solutions.

Conclusions: Policymakers must address comprehensive healthcare access, economic stability and social protections for LTS of HIV. HIV cure research must not undermine existing benefits or widen disparities. Ensuring LTS representation in decision-making is critical to developing equitable policies that safeguard their wellbeing before and after a cure.

Keywords: HIV cure research; United States; ageing; long‐term survivors; people with HIV; policy priorities; socio‐behavioural research.

PubMed Disclaimer

Conflict of interest statement

KD provides advisory services to Gilead Sciences, Inc. AbbVie, Inc. and Viiv Healthcare, Inc. MK reports historical funding to the institution from Gilead Sciences and ViiV Healthcare. LD reports historical AIDS Action Baltimore funding from ViiV Healthcare. JB provides advisory services to AbbVie, Gilead Sciences, Merck and Co., and ViiV Healthcare, and reports organizational funding from Gilead Sciences and ViiV Healthcare. JT provides advisory services to Abbvie and ViiV Healthcare, and receives organizational funding from Gilead Sciences & ViiV Healthcare. DA provides advisory services to Merck and Co, Gilead Sciences and ViiV Healthcare, and The Well Project receives organizational funding from Gilead Sciences, Merck and Co, and ViiV Healthcare.

Similar articles

References

    1. The Well Project . Long‐term survivors of HIV. 2023. https://www.thewellproject.org/hiv‐information/long‐term‐survivors‐hiv. Accessed 12/30/2024.
    1. Ahmed A, Taylor J, Diunugala SD, Lau R, Lai JC, Louella M, et al. “Sometimes they exclude us because of our age‐that's not right”: perceptions of HIV cure research among diverse long‐term survivors in the United States. AIDS Res Hum Retroviruses. 2025. Apr 23. 10.1089/aid.2024.0117w - DOI - PubMed
    1. Li Y, Liu H, Zhang S, Zhang Y, Wang H, Zhang H, et al. Demographic and clinical factors correlated with clinical outcomes among people with HIV treated by antiretroviral therapy: a retrospective cohort study. BMC Infect Dis. 2024;24(1):514. - PMC - PubMed
    1. Li N, Zheng HY, He WQ, He X, Li R, Cui W, et al. Treatment outcomes amongst older people with HIV infection receiving antiretroviral therapy. AIDS. 2024;38(6):803–812. - PMC - PubMed
    1. Mann SC, Castillo‐Mancilla JR. HIV, aging, and adherence: an update and future directions. Curr Opin HIV AIDS. 2020;15(2):134–141. - PubMed